sk&f 105809

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F 105809: prodrug to SK&F 105561; structure given in first source; dual inhibitor of arachidonic acid metabolism [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	129725
SCHEMBL ID	6581572
MeSH ID	M0186005

Synonyms (21)

Synonym
sk&f 105809
2-(4-methylsulfoxyphenyl)-3-(4-pyridyl)-6,7-dihydro[5h]-pyrrolo[1,2-a]imidazole
2-(4-methylsulfinylphenyl)-3-(4-pyridyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole
2-(4-methylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole
6,7-dihydro-2-(4-(methylsulfinyl)phenyl)-3-(4-pyridyl)-5(1h)-pyrrolo(1,2-a)imidazole
122454-69-7
skf-105809
unii-xnv1w9hm0o
xnv1w9hm0o ,
5h-pyrrolo(1,2-a)imidazole, 6,7-dihydro-2-(4-(methylsulfinyl)phenyl)-3-(4-pyridinyl)-
SCHEMBL6581572
2-(4-methylsulfinylphenyl)3 (4-pyridyl)-6,7-dihydro [5h]-pyrrolo[1,2-a]-imidazole
2-(4-methylsulfinylphenyl)-3-(4-pyridyl)-6,7-dihydro-[5h]pyrrolo[1,2-a]imidazole
2-(4-methylsulfinylphenyl)-3-(4-pyridyl)-6,7-dihydro-[5h]-pyrrolo[1,2-a]imidazole
(4-methylsulfinylphenyl)-3-(4-pyridyl)-6,7-dihydro-[5h]pyrrolo[1,2 a]imidazole
KSEJZTWORQXILM-UHFFFAOYSA-N
skf105809
2-[4-(methanesulfinyl)phenyl]-3-(pyridin-4-yl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole
DTXSID60924177
2-(4-(methylsulfinyl)phenyl)-3-(pyridin-4-yl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole
6,7-dihydro-2-(4-(methylsulfinyl)phenyl)-3-(4-pyridinyl)-5h-pyrrolo(1,2-a)imidazole

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	7 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.25 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.97	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	1.98	1	imidazoles
dinitrofluorobenzene Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.	1.98	1	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
thiazoles [no description available]	1.98	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
phenylbenzoquinone phenylbenzoquinone: RN given refers to parent cpd	1.97	1
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	1.98	1	D-galactosamine; primary amino compound	toxin
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.89	4	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite

Condition	Relationship Strength	Studies
Delayed Hypersensitivity [description not available]	1.98	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1
Endotoxin Shock [description not available]	6.98	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	1.98	1
Ache [description not available]	1.97	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	1.97	1
Contact Dermatitis [description not available]	1.97	1
Anasarca [description not available]	1.97	1
Innate Inflammatory Response [description not available]	2.38	2
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	1.97	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	1.97	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.38	2
Adjuvant Arthritis [description not available]	1.97	1
Primary Peritonitis [description not available]	1.97	1
Gastric Ulcer [description not available]	1.97	1
External Ear Inflammation [description not available]	1.97	1
Otitis Externa Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.	1.97	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	1.97	1
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	1.97	1

chemdatabank.com